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Mitochondria are essential organelles found in almost every cell in the human body. They 
host a number of important metabolic pathways and carry out essential biological 
functions such as ATP synthesis and regulating cell death. There is a slow decline in 
mitochondrial function associated with ageing and mitochondrial dysfunction is 
proposed to act causally in a number of diseases. Previously it has been difficult to 
measure the health of human mitochondria as tests have required tissue from invasive 
muscle biopsies. The Seahorse XF Analyser is a recent technological advance that enables 
researchers to test mitochondrial function in small numbers of live cells. Recently, using 
the Seahorse analyser, peripheral blood cells such as platelets, monocytes and 
lymphocytes have been shown to display individually distinct bioenergetic profiles. 
During circulation, these cells are exposed to metabolic or environmental stressors 
throughout the body, potentially allowing them to act as biomarkers of bioenergetic 
health and ageing.  Different cell preparations were trialled to purify and isolate platelets, 
monocytes and lymphocytes from freshly drawn whole blood. These protocols succeeded 
in preparing platelet and T-lymphocyte samples for XF analysis, however inconsistent 
results indicated that the protocols need further development. The Seahorse XF analyser 
was used to measure bioenergetic function in human platelets and T-lymphocytes from 
healthy donors ranging from 21 to 56 years of age. Each cell type required optimisation 
experiments to determine the optimal inhibitor and substrate concentrations to generate 
a meaningful bioenergetic profile. Similarly, seeding densities were determined to ensure 
oxygen consumption values that were suitable to the instruments sensitivity. These cell 
types have elastic metabolic phenotypes, and appeared sensitive to metabolic switching 
during early stages of the XF assay. Platelets were particularly difficult to work with 
because of their inclination to cease using oxidative phosphorylation and switch 
metabolism to using purely glycolytic pathways. Platelet susceptibility for metabolic 
switching is undetermined at this point. Lymphocyte optimization experiments also 
indicated possible premature activation during the assay. Further work is needed to fine 
tune this protocol to ensure consistent and uniform measurements before accurate BHI 
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Chapter One:  Introduction 
 
1.1 Overview 
A mitochondrion is a discrete double-membrane-bounded organelle found in all 
eukaryote organisms, a group which encompasses all plants, animals, fungi and protists 
(1).  A binding relationship was forged with these intracellular symbionts during a 
chapter of the eukaryote’s greatly-distant evolutionary past (2). Consequently, these 
cellular residents now inhabit all human cells, with the only exception being erythrocytes 
(3).  In humans, the most prolific role of mitochondria is the synthesis of adenosine 
triphosphate (ATP), a ubiquitous energy storage molecule of the cell. ATP synthesis 
requires a coordinated set of biochemical reactions which occur in and around the 
mitochondrial inner membrane in a process known as oxidative phosphorylation 
(OXPHOS). Central to the OXPHOS system is a chemical reaction which involves the 
reduction of molecular oxygen to water making OXPHOS, the predominant consumer of 
the oxygen we breathe and the major component of cellular respiration (4).  In addition 
to ATP synthesis, mitochondria play host to a number of important metabolic pathways - 
the tricarboxylic acid  (TCA) cycle, β-oxidation, lipid and cholesterol synthesis  – as well 
as regulating cell death and carrying out intracellular signalling through the production 
of reactive oxygen species (ROS) (5, 6). Mitochondria are organelles of power and 
influence whose function is fundamental to the cell life and death. 
The central components of OXPHOS are illustrated in Figure 1.  Four protein complexes - 
labelled I through IV - are known collectively as the electron transport chain (ETC). Three 
of these complexes combine substrate reactions with the pumping of protons from the 
mitochondrial matrix to the intermembrane space. Complex II, while incapable of proton 
pumping, facilitates electron transfer within the transport chain. Electrons are donated 
through oxidation of nicotinamide adenine dinucleotide (NADH) and succinate, which are 
endogenous substrates generated from the TCA cycle. The terminal electron acceptor of 
the ETC is molecular oxygen, which is subsequently reduced to form H2O at complex IV. 
The directional pumping of proton ions into the intermembrane space creates a proton 
motive force (PMF) across the inner membrane in the order of 200 mV (7). A proton 
circuit is formed when the PMF drives protons re-entry into the matrix through a 
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transmembrane ATP synthase. Proton passage provides the energy to release a newly 
phosphorylated ATP from the catalytic domain of the synthase protein. Together, these 
bioenergetic transformations form a tightly coupled system which can be measured by 
monitoring oxygen reduction occurring at complex IV. As such, the OXPHOS system is 
measured indirectly by measuring cellular respiration (8). 
 
Figure 1.1  Oxidative phosphorylation and the proton circuit of the mitochondrial 
inner membrane: Protons are pumped into the intermembrane space by complexes I, III 
and IV and return via the ATP synthase, generating ATP. The proton circuit is coupled with 
the oxidation of substrates (NADH and succinate) and electron transfer through the 
electron transport chain which terminates with the reduction of molecular oxygen to water 






1.2 Mitochondrial Damage 
 
Mitochondria numbers within a cell type are variable and dynamic. The population flux 
is managed by the contrasting biological processes of biogenesis and mitophagy, the 
latter being the non-random mitochondrial degradation by autophagy (9). Biogenesis 
involves the growth and division of pre-existing mitochondria. Due to their unique origin, 
mitochondria contain their own genome, which exists as numerous copies of circular 
double-stranded mitochondrial DNA (mtDNA) molecules and can number in the 
thousands per cell (10, 11). The great majority of mitochondrial proteins are encoded by 
nuclear DNA (nDNA); however, an important subset is still encoded by the 
mitochondria’s own genome. Successful biogenesis requires mtDNA replication and the 
synthesis and transport of thousands of necessary proteins (12). These multitudes of 
proteins and DNA components are each susceptible to damage. As mtDNA has no histone 
proteins, mutations accumulate 10-20 times faster than in nuclear genes (13), though 
mutations in either DNA type can greatly effect mitochondrial function.  
Protein complexes I, II, and III of the ETC contain reactive sites where unpaired electrons 
can leak onto molecular oxygen, forming superoxide anion radical O2 ̄ (5).  This free 
radical species can rapidly dismutate to hydrogen peroxide (H2O2) in a reaction that can 
occur spontaneously or be catalysed by the enzyme superoxide dismutase (SOD) (5). It is 
estimated that mitochondria are responsible for the majority (~90%) of cellular ROS 
production (14). ROS can cause lipid peroxidation and oxidative damage to surrounding 
membranes and biomolecules (15), meaning locally generated ROS can directly damage 
any of the ETC proteins, TCA cycle enzymes and nuclear or mtDNA (16). Thus 
mitochondria are both a major source and target of ROS damage (17). The ongoing 
confrontation of oxidative damage is emphasised by the extensive array of antioxidant 
defences present in mitochondria (10). Despite these defences, mitochondria have the 
potential to perpetuate oxidative damage, which contributes to their own damage and 
dysfunction. Without adequate mitophagy, damaged or dysfunctional mitochondria 
contribute further ROS production and oxidative stress that may lead to damage and 
dysfunction of surrounding cellular components.  A declining turnover rate of 
dysfunctional cellular components is considered to contribute to the deterioration of 
tissues and organs seen with ageing (18), hence the orderly turn-over of damaged 
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mitochondria is critical to limit these undesirable effects of ageing (9). Unsurprisingly, 
dysfunctional mitochondria and deficient mitophagy have been suggested as leading 
causes of aging due to the resulting increase in mtDNA mutations and oxidative stress 
(10, 14, 19, 20). As such, mitophagy has recently garnered interest in ageing and longevity 
studies (21). 
 
1.3 Mitochondrial Dysfunction and Disease 
 
Given their ubiquitous presence and precarious biology, it seems intuitive that 
dysfunctional mitochondrial will play a role in disease. The archetypal mitochondrial 
diseases cause obvious and chronic debilitation in sufferers. These diseases are genetic 
disorders caused by defects in mitochondrial or nuclear DNA and may be either inherited 
or arise through spontaneous biological damage (10, 22). Historically these diseases have 
been identified and classified by the dominant disablement they cause (23). The best 
known are mitochondrial myopathies, which have been recognized since the 1960s as a 
collection of syndromes with common symptoms of muscle weakness and exercise 
intolerance (24).  
Aside from chronic mitochondrial diseases, mtDNA mutations are also observed to occur 
in other human diseases, including colon and prostate cancer (25, 26), positing the 
question of whether mitochondrial dysfunction may play a causal role in these diseases. 
Dysfunctional mitochondria have therefore become a focal point in the investigation into 
common human diseases. The same self-perpetuating damage and dysfunctions thought 
responsible for the ageing process are also believed to contribute to age-related 
neurodegenerative disorders such as Alzheimer’s disease (AD) (27). In fact, there is 
evidence that mitochondrial dysfunction not only occurs early in all types of 
neurodegenerative disease, but also acts causally in the pathogenesis of these diseases 
(10).  
Based on the notion that failure to remove damaged mitochondria will cause 
deterioration in bioenergetics function (28), a recent trend in translational research has 
been to investigate bioenergetic dysfunction in disease sufferers. Energetic abnormalities 
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have been demonstrated in a host of common and progressive diseases, including 
diabetes (29), neurodegeneration (10, 19), cardiovascular disease (30) and cancer (31, 
32). These studies identify varying abnormalities between diseased and healthy controls 
without positing a causative mechanism. They do, however, bolster the notion that 
mitochondrial dysfunction may play a greater role in human disease than is currently 
recognized. 
 
1.4 Measuring Mitochondrial Dysfunction 
 
Abnormality in any of the biological processes that mitochondria perform can be 
considered mitochondrial dysfunction. Frequently, however, dysfunction is measured in 
terms of the canonical role of ATP synthesis by OXPHOS. As OXPHOS is central to many 
of the physiological functions of the mitochondria it provides a critical measure to 
encompass a wide variety of dysfunctions (33). Two predominant measurement types 
are employed to measure the OXPHOS: 1 - quantify the potential of the PMF, and 2 - 
quantify the proton flux or ‘current’ through the system. The proton current is measured 
indirectly via the reduction of molecular oxygen at complex IV, made possible due to the 
tight coupling of the reactions of the ETC complexes and proton pumping into the 
mitochondrial intermembrane space. This relationship holds for both isolated 
mitochondria and cells (34).  
 
The earliest methods of measuring oxygen consumption used a Clarke-type oxygen 
electrode (35) that was developed by Chance and Williams to measure OXPHOS of 
isolated mitochondria in suspension (36). In these classical experiments, mitochondria 
are isolated, purified and subsequently incubated in suspension under different substrate 
and extracellular conditions in order to measure defined respiration states. Assays were 
restricted to cells which could be obtained in high yields, and as a result, nervous tissue 
and liver cells were the main sources for samples used in assays (37, 38). Despite the 
sample limitations, experiments were able to measure a range of OXPHOX components, 
including substrate transport and metabolism, electron delivery to the ETC, the activities 
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of protein complexes, ATP synthesis, proton leak and more (33). Collectively these 
measurement parameters came to represent mitochondrial bioenergetics.  
 
The preceding years saw many developments in the technology of measuring oxygen 
consumption. Cell respirometers using coverslip-attached cells incorporated continuous 
monitoring of the cellular respiration (39). This technology employed an isolated ∼130-
μl volume chamber with polarographic oxygen electrodes at both the inlet and outlet 
ports of the chamber. These dynamic measures made oxygraphy – traces of oxygen 
consumption over time – the representative measure of mitochondrial bioenergetics. 
Concurrently, assays were developed using 96 well plates integrated with fluorescent 
sensors (40). Meanwhile, the Oroboros, a benchtop micro-respirometer, greatly 
advanced software and calibration procedures (41). Together these technical advances 
set the scene for development of the Seahorse Bioscience extracellular flux (XF) analyser 










The Seahorse instrument uses fluorimeters to detect dissolved oxygen (O2) and free 
proton concentration (H+) in the extracellular media. This is performed by pairs of solid 
state probes built into a sensor cartridge which sits above and covers the multi-well 
microplate that contains the samples (Figure 1.3). The cartridge sensors are 





automatically lowered to 200 microns from the well bottom during each measurement 
cycle, creating a transient 7 µl volume chamber from within which changes in real-time 
O2 and H+ concentration are measured [17]. Measuring the change in these 
concentrations over a prescribed time-frame gives either the oxygen consumption rate 
(OCR, pmol/min) or extracellular acidification rate (ECAR, mpH/min). The cartridge also 
contains four injection ports per sample well, allowing for the introduction of soluble 
additives to each well at desired points during the assay. The multi-well, automated, high 
throughput assay allows versatility in experimental design. It may be used on intact 
viable whole cells [17] or on isolated mitochondria [37], and permits the ability to 
measure OXPHOS in a more physiologically relevant context. 
 
Figure 1.3 How the XF instrument works: The Seahorse instrument uses retractable 
probes and inbuilt delivery ports to facilitate dynamic measurement of O2 and H+ 







1.5 Mitochondrial Stress Test and Bioenergetic Health Index 
 
The mitochondrial stress test is a protocol for measuring mitochondrial bioenergetic 
function using the Seahorse XF analyser (Figure 1.4). During a stress test the OCR of a cell 
population is measured at consecutive time points and under varying conditions brought 
about by the addition of modulators to the extracellular media. Once a stable basal 
respiration rate is established the drug oligomycin (Oli) is introduced to inhibit the ATP 
synthase by blocking proton passage. The resulting decrease in OCR reveals the 
respiration previously attributable to ATP production. Next the ionophore FCCP 
(carbonyl cyanide p-trifluoromethoxyphenylhydrazone) is introduced to uncouple the 
proton gradient across the inner mitochondrial membrane from the pumping of protons 
by the ETC. FCCP is a mobile ion carrier that allows pumped protons to rapidly cycle from 
the intermembrane space back into the mitochondrial matrix. The resulting 
depolarisation of the inner membrane allows the ETC components to operate at a greater 
rate, resulting in an OCR measurement that represents the maximal mitochondrial 
respiration rate. The difference in OCR between the maximal and basal measurements is 
termed the spare reserve capacity and is used to measure the ability of OXPHOS to 
accommodate rapid rises in metabolic demand (42). Finally, an inhibitor of the ETC 
(antimycin A) is introduced to stop the reduction of oxygen occurring at complex IV. The 
residual OCR is deemed attributable to non-mitochondrial respiration and is subtracted 
from all other measures. This modulator also allows for measurement of proton leak 
occurring across the inner–membrane.  
 
  
Figure 1.4  The mitochondrial stress 







To capitalise on the ability of the mitochondrial stress test to measure multiple aspects 
of mitochondrial bioenergetics, Chacko et al. (2014) proposed integrating the critical 
measurement parameters into a single metric which they termed the bioenergetic health 
index (BHI) (28). This single composite value (Figure 1.5) could be used to monitor and 
compare a person’s mitochondrial function over time and potentially to make 
comparisons between individuals.  
 
 
Figure 1.5 The bioenergetic health index  
 
1.7 Measuring Mitochondrial Bioenergetics in Human Blood Cells 
 
To screen human populations an easily accessible source of mitochondria is required. The 
Seahorse XF analyser allows for bioenergetic measurement of intact cells sourced from a 
host of tissue samples or cell cultures. One such source has been cells isolated from 
freshly drawn whole blood. Of these, platelets have tended to be the popular choice of 
sample for XF analysis since the introduction of the Seahorse instrument (43-45). This is 
due in part to their abundance and distribution throughout the circulatory system. 
Platelets are anucleate cells and so provide a model with a much diminished scope for 
mitochondrial repair and biogenesis. 
 
A study by Avila et al. (2011) used platelet mitochondria as a biological sensor to 
investigate the systemic effects of  Type 2 diabetes mellitus (T2DM) (43). XF analysis 
using the Seahorse revealed platelets in the T2DM cohort to have diminished oxygen 
consumption and ATP turnover when compared to the insulin sensitive control group 
(n=8). Further investigations showed up-regulation of mitochondrial anti-oxidant 
enzymes, which was described by the author as a ‘stress-signature’ of the disease. It was 
suggested that this phenomenon is possibly due to the platelets’ exposure to oxidative 
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stresses early on in their life cycle while they are present in the bone marrow 
compartment. Despite the relatively small sample size, these findings highlight the use of 
blood cells as a surrogate for assessing the systemic effects of disease in remote parts of 
the human body. This idea has become known as the biological ‘canary in the coal mine’ 
(46).  
 
The scope of the XF analysis was validated in a 2014 study by Cardenes et al. (44). In this 
work, platelet bioenergetics were measured in patients with sickle cell disease (SCD) and 
subsequently compared against control measurements taken from a healthy population. 
SCD patients are known to exhibit aberrant platelet activation, but the mechanism 
remains unknown. XF analysis revealed a significant decrease in basal respiration 
(~30%) and proton leak (~32%). A subsequent enzyme activity assay then identified a 
marked decrease in ATP synthase activity (~36%) despite protein expression assay 
being similar in both groups. The group then conducted further experimentation to show 
significant correlation between the bioenergetic alteration and aberrant platelet 
activation, suggesting a causal relation. In addition, it was demonstrated that - when 
normalised to cell count - the data from XF analysis is consistent with Clarke electrode 
assay and that the percentage of activated platelets did not change from before and after 
the XF experiment. Cardenes et al.’s study demonstrates the investigative potential of XF 
analysis when conducted on cells isolated from easily obtained blood samples. While it 
must be recognised that the cell type was known to be dysfunctional, the cohort provides 
an effective positive control for this type of study.  
 
In 2015 a number of experiments have been published which use XF analysis on platelets 
to measure mitochondrial function. The mitochondrial stress test and BHI have been used 
to test and compare the bioenergetic performance of fresh isolated compared with stored 
platelets (47), and platelets have been used to demonstrate a systemic metabolic 
alteration in asthma patients (48). Significant new research has investigated the effects 




Perhaps in a follow up of Avila et al.’s research (43), Hartman et al. (2014) used XF 
analysis to assay peripheral blood mononuclear cells (PBMC) in T2DM patients (50). This 
research group used a mixture of PBMCs isolated through centrifugation and layer 
separation. Fluorescence activated cell sorting (FACS) revealed that samples obtained by 
this method contained 82% lymphocytes and 14% monocytes. Results showed that OCR 
was higher for basal and maximal respiration measurements in diabetic patients 
compared to control. The group also go on to demonstrate a pattern of mitochondrial 
oxygen consumption consistent with higher production of reactive oxygen species. While 
the benefits of testing a mixture of PBMCs are unclear, this study shows a development 
of the blood cell assay concept by testing lymphocytes and monocytes.  
 
Around a similar time the utility of assaying blood cell types separately was investigated 
by Chacko et al. (2013). In this methods paper the group established that each of  four cell 
types has both distinct bioenergetics and distribution of ETC complexes (51). Neutrophils 
were shown to have comparatively low OCR when compared to platelets, monocytes and 
lymphocytes, and were found to be relatively unresponsive to modulation factors typical 
of these assays. These two studies nicely validate the use of monocytes and lymphocytes 
along with platelets in XF analysis of mitochondrial bioenergetic function. 
 
Following multiple studies measuring mitochondrial function in PBMCs or platelets (43-
45, 50, 52) a comprehensive protocol was recently published by Kramer et al. (2014) 
which outlines methods to isolate, purify and measure the bioenergetics of four 
peripheral blood cell types (53). This assay was designed to be conducted on a single 20 
ml sample of freshly collected blood and serves as a proof of concept that parallel XF 
experiments may be used as a clinical assay to measure bioenergetic dysfunction. Also 
included in this report is cursory data from 6-8 healthy donors, which serves as a 
guideline for replication of this methodology. The authors again expound the idea of using 
these cell types as surrogates or ‘biomarkers’ for global metabolic changes, and indicate 







Mitochondria are a source of ROS that can cause oxidative damage to themselves or 
surrounding biomolecules. Damaged mitochondria if not adequately recycled can 
propagate further oxidative damage, and in so doing may be contributing to the 
pathogenesis of disease and ageing. The Seahorse XF analyser allows dynamic 
measurement of mitochondrial bioenergetic function in peripheral blood cells isolated 
from small samples of freshly drawn whole blood. Each blood cell has distinct lifecycles 
and energetic profiles. They are exposed to systemic metabolic and inflammatory 
stressors during their maturation and circulation. Measuring their bioenergetic function 
may offer insight into oxidative damage and disease occurring throughout the body. By 
combining individual bioenergetic parameters into a single index, it may be possible to 
measure and compare an individual’s mitochondrial function and to make a quick and 
basic diagnosis of mitochondrial dysfunction. 
 
1.9 Thesis Aims 
 
1. To use the mitochondrial stress test to assay mitochondrial bioenergetics of 
peripheral blood cells (platelets, monocytes and lymphocytes) from individuals 
constituting a healthy control population, and to use this data set to compile a 
representative BHI for each distinct cell type. 












Table 2.1.  Materials used in this thesis 
Antibodies: Supplier Location 
CD3-PE (UCHTi) Beckman Coulter Brea, CA, USA 
L243 (HLA-DR) ATCC Rockville, MD, USA 
OKMI (CD11B) ATCC Rockville, MD, USA 
Goat Anti-Mouse IgG MicroBeads Miltenyi Biotech Bergisch-Gladbach, 
Germany 
MACS nanoparticles   Miltenyi Biotech Bergisch-Gladbach, 
Germany 
   
Media:   
RPMI (1640) Sigma-Aldrich St Louis, MO, USA 
XF Assay Medium (2mM GlutaMAX™) Seahorse Biosciences North Billerica, MO, 
USA 
XF Base Medium  (no glutamine) Seahorse Biosciences North Billerica, MO, 
USA 
   
Modulator Drugs:   
Antimycin A Sigma-Aldrich St Louis, MO, USA 
FCCP Sigma-Aldrich St Louis, MO, USA 
Oligomycin Sigma-Aldrich St Louis, MO, USA 
Prostacyclin (PGI2) Sigma-Aldrich St Louis, MO, USA 
   
Seahorse Consumables:   




XF24 Cell Culture Microplates Seahorse Biosciences North Billerica, MO, 
USA 
XF24Sensor Cartridge Seahorse Biosciences North Billerica, MO, 
USA 
    
Miscellaneous:   
Tris Sigma-Aldrich St Louis, MO, USA 
Triton X Bio-Rad Laboratories Hercules, CA, USA 
Cell TakTM Corning 
Incorporated 
Life Sciences 
Tewksbury, MA, USA 
 
 
2.1.1  Buffers and Media 
 
Lysis Buffer: 10 ml Triton® X-100 (final concentration 1% Triton® X-100 in buffer), 10 
ml of 1M Tris, 980 ml sterile H2O. 
RPMI-1640: Supplement with 0.3 g/L L-glutamine. 
XF Base Medium (minimal DMEM): contains no sodium bicarbonate (buffering agent), 
glucose, glutamine/GlutaMAXTM, or sodium pyruvate.  
XF Assay Medium: modified DMEM, 0mM Glucose, 2 mM L-Glutamine 
XF-DMEM: XF assay medium with supplemented with 25 mM D-glucose, 1 mM pyruvate 






2.2  Methods 
 
2.2.1  Cell Preparation Protocols  
 




Venous blood was drawn into 9 ml EDTA vacuum tubes and the first 2 ml of blood was 
discarded to avoid artificial activation due to venepuncture. Platelets were isolated by 
differential centrifugation as follows: Whole blood was centrifuged with a room 
temperature (RT) swinging-bucket rotor at 500 x g for 15 min with brake 5/acceleration 
0 (B5/A0). Platelet rich plasma (PRP) was collected and allowed to sit for 30 min (RT) 
before pelleting by centrifugation at 750 x g 10 min (B9/A5). The plasma was removed 
and the pellet re-suspended in 5 mL of PBS supplemented with 1 µg/mL prostacyclin 
(PGI2). The suspension was washed by centrifugation at 750 x g 10 min (B9/A5) and re-
suspended into 1 mL of PBS+PGI2. Platelet count was determined by turbidimetry using 
a spectrophotometer (800 nm) as described by Walkowiak et al. (54). The volume 
corresponding to the desired concentration was pelleted by centrifugation at 500 x g 5 
min (B9/A5) and re-suspended in the appropriate volume of warm sterile XF base media. 
 
Peripheral Blood Mononuclear Cells (PBMCs) 
 
Venous blood was drawn into 9 ml EDTA vacuum tubes and centrifuged with a swinging-
bucket rotor at 500 x g for 15 min with brake 5 after which the PRP was collected. The 
PBMC layer was transferred to sterile 50 ml conical tubes and diluted 4x with basal RPMI. 
Diluted blood was overlaid onto 15 ml of Ficoll (RT) and centrifuged at 1000 x g for 20 
min (B5/A0). The middle band containing PBMCs was carefully collected without 
disturbing the surrounding bands and diluted 4x with basal RPMI.  The suspension was 
centrifuged at 700 x g 10 min (B9/A5), re-suspended in 1 ml RPMI containing 5% FCS 
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(RPMI-FCS), pelleted again and re-suspending in 80 µl RPMI+FBS. Twenty µl of magnetic 
bead labelled antiCD14 antibody was added for positive selection of monocytes and 
followed by incubation for 15 min at 4 °C. Cells suspension was then washed with 1 ml 
RPMI+FBS, pelleted by centrifugation at 700 x g 10 min (B9/A5) and re-suspended in 500 
µl RPMI+FBS. Magnetic-activated cell sorting (MACS) columns were prepared by washing 
with 3 ml of RPMI+FBS while placed in the column of the MACS separator. Cell 
suspensions were added to the columns and immediately washed three times with 3 ml 
of RPMI+FBS. The cell suspension flow through was collected into sterile 15 ml flacon 
tubes. Monocytes were isolated by removing the column from the magnetic field of the 
MACS separator and eluted into a sterile 15 ml flacon with 5 ml of RPMI+FBS using a 
column plunger. Lymphocytes were isolated by pelleting the flow-through wash fraction 
at 300 x g for 10 min (B9/A5) and resuspension in 80 µL of RPMI+FBS. 20 µl each of 
magnetic beads labelled antiCD61 and anti235a antibodies were added to positively 
select out platelets and erythrocytes, followed by incubation for 15 min at 4 °C. Cells 
suspension was then washed with 1 ml RPMI+FBS, pelleted by centrifugation at 700 x g 
10 min (B9/A5) and re-suspended in 500 µl RPMI+FBS. The cell suspension was added 
to the MACS column and immediately washed three times with 3 ml of RPMI+FBS. The 
cell suspension flow through was collected into sterile 15 ml falcon tubes. Cell fractions 
were then pelleted at 700 x g 10 min (B9/A5) and re-suspended in 1 ml warm sterile XF 
base media for counting using a haemocytometer. 
 
T lymphocytes (T cells) 
 
Whole blood was collected into 6 x 9 mL EDTA tubes and diluted 1:1 with PBS.  Diluted 
blood was layered onto 25 mL of 15 mL Ficoll in 4 x 50 mL falcon tubes.  Tubes were spun 
at 1000 x g for 20 min (no acceleration or brake) in a swinging bucket centrifuge.  PBMC 
layer was carefully removed into 2 x 50 mL falcon tubes, made up to 50 mL with 
RPMI+FBS and centrifuged at 500 x g for 5 min with brake.  Pellets were re-suspended, 
combined and made up to 50 mL with RPMI+FBS.  PBMS cells were counted by 
haemocytometer before cell solution was centrifuged at 300 x g (with brake) for 5 min 
and re-suspended in antibodies as follows: Target cell types (monocytes, B cells, NK cells) 
were calculated at 50% of total cells counted. Monoclonal antibodies (mAb) used were 
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produced in house from hybridomas obtained from American Type Culture Collection 
(ATCC).  Fifty µL of each mAb were added per million target cells using OKMI (CD11b) for 
monocytes and L243 (HLA-DR) for monocytes, NK cells and B cells.  Cell-mAb solution 
was placed on ice for 20 min then made up to 50 mL with RPMI+FBS and centrifuged at 
350 x g for 5 min (with brake) and re-suspended in 250 µL RPMI+FBS.  Ten µL per million 
targets of goat anti-mouse IgG microbeads were first washed with 2 mL RPMI+FBS in a 
magnetic field then added to cell mAb solution.  Tubes were placed on ice for 30 min with 
regular agitation.  Cell-mAb-microbead solution was made up to 2 mL with RPMI+FBS 
and supernatant was collected while tube was placed within a magnetic field.  Collection 
was repeated with a further 2 mL of RPMI+FBS.  The supernatant containing purified T 
cells was counted using a haemocytometer. T cell purity was measured using CD3-PE 
incubation (15 min) and flowcytometry.  T cell solution was pelleted at 300 x g for 5 min 
(with brake) and re-suspended to the appropriate concentration with warm XF-DMEM 
media. 
 
2.2.2  Seahorse Extracellular Flux (XF) Analysis 
 
Preparation of XF24 Sensor Cartridge 
 
On the day prior to the assay the XF24 sensor cartridge was hydrated by adding 1 ml of 
the XF calibrant solution to the utility plate and lowering the sensor cartridge to 
submerge the sensors. The cartridge was placed in a non-CO2 37 °C incubator overnight 
until required. Modulator drugs were made up with sterile XF base media and 
loaded into cartridge injection ports immediately before the commencement of the 
XF assay. 
 
Preparing the XF- DMEM 
 
XF assays require a non-buffered medium to accurately measure the extracellular 
acidification rate (ECAR). Two media types were used in assays (XF Base medium and XF 
Assay medium). Each was set to pH 7.35 ± 0.5, filter sterilised and kept warm in a 37 °C 
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water bath. XF base media was supplemented with 25 mM D-glucose, 1 mM pyruvate and 
2 mM L- glutamine. XF assay media was supplemented with 25 mM D-glucose, 1 mM 
pyruvate and 4 mM L- glutamine. 
 
Plating of Cells 
 
Cell-tak cell adhesive was freshly prepared to the recommended concentration for XF24 
microplates of 2.4 µg/ml adjusted to pH 7.2-7.8 using 1M NaOH. 50 µl of the Cell-tak 
solution is applied to each well of the microplate and after 20 min was washed twice with 
200 µl of PBS and aspiration. The plate was air dried for an additional 20 min then 
warmed to room temperature in the cell culture hood before seeding. One hundred µl of 
the desired cell suspension was seeded using a multipipettor pipette to the side of each 
of the 20 wells. Four additional wells remained unseeded to be used for background 
temperature and pH determination.  The cell pate was centrifuged at 200 x g for 1 sec 
with no brake, rotated 180° and centrifuged again at 300 x g for 30 sec (no brake). Cells 
were incubated (not supplemented with CO2) for 30 min at 37°C before being topped up 
with 500 µL of warm XF base media (at the top-side of the well wall) and further 
incubated for 15-25 min. Cells were observed under a microscope before being placed in 
the XF analyser. 
 
2.2.3  XF Assay Protocol 
 
The XF assay protocol was set to measure the change in dissolved O2 concentration from 
within a fixed 7µl volume of extracellular media over a four minute time period. The 
resulting metric is the oxygen consumption rate (OCR) which is given as is an indicator 
of mitochondrial respiration and is expressed as picomols per minute (pmol/min). 
Absolute OCR measurements are recorded at 8 minute intervals. Each begins with 2 
minutes of agitation to allow the extracellular media to mix, followed by 2 minutes of 
waiting time and 4 minutes of measurement upon the formation of the transient fixed 
volume micro-chamber, giving a mix/wait/measure setting of 2/2/4 min. Each drug 
injection is followed by two subsequent OCR measurements. Five consecutive 
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measurement points were made to establish a steady basal respiration period before the 
first drug oligomycin (0.75 µM) was injected into the extracellular media to inhibit ATP 
synthase. FCCP (variable) was then injected to uncouple the proton gradient across the 
inner mitochondrial membrane, and antimycin A (10 µM) was added to inhibit complex 
3 and consequently the ETC.   
The individual bioenergetics parameters of OXPHOS as illustrated in Figure 1.4 were 
calculated as follows:  Non-mitochondrial respiration = minimum rate measured after 
injection of Antimycin A. Basal respiration = (last rate measured before Oligomycin 
injection) – (non-mitochondrial respiration rate). Maximal respiration = (maximal rate 
measured after FCCP injection) – (non-mitochondrial respiration rate). ATP production 
= (last rate measured before Oligomycin injection) – (minimum rate measured after 
Oligomycin injection). Proton leak = (minimum rate measured after Oligomycin 
injection) - (non-mitochondrial respiration rate). Spare reserve capacity = (maximal 
respiration – basal respiration).  
 
2.2.4   Protein Assay 
 
The XF media was carefully aspirated from each well. 20 µl of lysis buffer was added to 
each well, mixed with pipette and allowed to sit for 5 mins (RT). 2 µl of cell lysate was 
added to the Direct Detect® infrared spectrometer assay cards which were dried at 37°C 








Platelets were isolated and purified by differential centrifugation as described in Section 
2.2.1. Typically, 4 x 9 ml EDTA tubes were used to isolate ~1-2 x 109 platelets, providing 
enough cells to seed all 20 available wells at the initial seeding density of 50 x 106 
platelets per well. Prostacyclin (PGI2) was used to inhibit platelet aggregation during 
pellet re-suspension. PGI2 acts by antagonizing thromboxane A2 and stimulating platelet 
adenylyl cyclase (55). It was found necessary to make up PGI2 in sterile H2O at a pH of 11 
and store single use aliquots in a -80 °C freezer. Platelets responded best to pelleting and 
re-suspension after at least 30 minutes’ rest following the initial whole blood PRP spin. 
Cell Tak and plate centrifugation was found to successfully adhere platelets to the well 
floor for the duration of the 88 minute assay. Density experiments found that under the 









to XF24 well plate. 
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3.1.1  Mitochondrial Stress Test 
 
Oxygen consumption rate was calculated at every measurement point for each of the 20 
wells of the XF24 plate used in the mitochondrial stress test. Every well produced its own 
individual bioenergetic trace (Figure 3.2), which, combined, give a mean value for each 
technical replicate within a group. A representative mean bioenergetic trace from a 
mitochondrial stress test is shown in Figure 3.3. Basal respiration was stable before the 
addition of modulating drugs, which once injected into the extracellular media were able 
to successfully isolate the desired components of OXPHOS as expected. 
 
Figure 3.2.  Individual bioenergetics traces from a mitochondrial stress test. Plate 









Figure 3.3.  Representative mean bioenergetics trace from a mitochondrial stress 
test. 3 Plate K, 40 x 106 platelets per well, FCCP = 0.6µM. Data represent mean values from 
17 wells ± standard deviation. 
 
 
During the same measurement periods the change in proton concentration was also 
measured against time to determine the extra-cellular acidification rate (ECAR), which is 
predominantly a measure of lactic acid formed during glycolytic energy metabolism 
(Figure 3.4). For the same experiment, a low and stable ECAR value was observed during 
the basal measurement period. Upon the introduction of oligomycin a rapid increase in 
ECAR was observed, which is reflective of increased glycolytic metabolism due to the 









Figure 3.4 Representative platelet ECAR trace from a mitochondrial stress test. 
Plate K, 40 x 106 platelets per well, FCCP = 0.6µM. Data represent mean values from 17 wells 
± standard deviation. 
  
The individual OXPHOS bioenergetic parameters of the same representative experiment 
are given in the bar graph in Figure 3.5. OCR is given here as absolute values before 
normalisation.  
Figure 3.5 Bioenergetics parameters of OXPHOS - platelets. Plate K. Data represent 




































The same bioenergetic parameters can be represented as a percentage of basal 
respiration, as shown in Figure 3.6. This has the effect of normalising the parameters 
relative to basal respiration, and counteracting any variation in cell seeding number that 
may occur between experiments. 
 
Figure 3.6 Bioenergetics parameters of OXPHOS as a percentage of basal 
respiration - platelets. Plate K, 40 x 106 platelets per well, FCCP = 0.6µM. Data represent 
mean values from 17 wells ± standard deviation. 
 
Four of the bioenergetic parameters are represented in the single index termed the 
bioenergetic health index (BHI) (Figure 1.5) as developed by Dr. Victor Darley-Usmar at 
the University of Alabama at Birmingham. For this basic derivation the exponents for 
each parameter of the equation are set to one. The BHI for the same representative 
experiment is shown in Figure 3.7. Individual BHI values are calculated for each well and 
then averaged to provide the mean BHI for that group. One additional well has been 









































Figure 3.7 BHI for platelets – plate K.  A single metric encompassing four 
bioenergetic parameters measured by the mitochondrial stress test. (a) BHI calculated 












































3.1.2  Abnormal Results 
 
12 platelet mitochondrial stress tests assays were conducted using blood donated from 
10 individuals (6 female, 4 males) ranging from 21 to 56 years of age. These preliminary 
experiments were carried out to optimize important aspects of the stress test assay such 
as cell seeding density, FCCP concentration and glutamine media supplementation. Each 
assay involved seeding 20 available wells - of the XF24 plate - with platelets belonging to 
a single healthy donor. Groups of 4 or 5 technical replicates were allocated to each 
variable being examined, while the other assay parameters stayed uniform. To varying 
degrees each experiment contained wells with abnormal results, with OCR or ECAR 
measurements differing from the characteristic response reported in Figures 3.3 and 3.4. 
The abnormal wells were consequently omitted from normal results data.  There 
appeared to be four different types of abnormal response which were categorised by the 
following criteria: 
(1) Well displayed a metabolic switch to glycolysis, shown by a high or increasing ECAR 
during the basal measurement period and a declining or erratic OCR. 
(2) OCR showed a normal pattern, but the absolute value fell outside two standard 
deviations of the mean of that group. 
(3) OCR was comparatively unresponsive or showed uncharacteristic response to 
modulators. 
(4) Well failed to establish a stable basal OCR during the basal measurement period. 
 
A representative illustration of each criterion is shown in Figure 3.8, and a schematic of 
each 24 well plate used in the 12 experiments is shown in Figure 3.9. In the latter figure, 
each abnormal well is assigned a number (as above) to categorise their omission criteria. 
A supplementary table is included (Table 3.1) to detail each experiment type and list the 
experimental parameter being optimised. In this table the total number of abnormal wells 
is listed along with the frequency of each of the four classification criteria. The abnormal 
wells are further colour coded to aid in visualising patterns and frequencies. The number 




Figure 3.8 Demonstrative traces of the four criteria used to categorise abnormal 
results. Bioenergetic traces are given to illustrate the pattern seen in each qualifying 
criterion. 
 
Experiments from plates G, H and L have half or more wells being omitted. Others such 
as plates B, J and K show relatively small occurrences. Five plates (C, F, G, H, and L) have 
the highest frequency of outliers which fall under criterion 1, while four plates (A, B, E, 





Figure 3.9  Schematic of each of 24 well cell-plates used in 12 optimisation 
experiments. Each numbered square represents an abnormal well excluded from results 






Table 3.1. Record of twelve platelet optimisation experiments.  
 
3.1.3  Metabolic Switch to Glycolysis 
 
Criterion 1 wells have displayed a metabolic switch to glycolysis as shown by a high or 
increasing ECAR during the basal period and a declining or erratic OCR. These contrasting 
bioenergetic traces are illustrated in Figure 3.10, which shows OCR and ECAR traces for 
normal and abnormal wells (plate G). OCR begins near normal levels for the first 
measurement point and then quickly declines over the next few measurement points to 
sit at approximately the level of non-mitochondrial respiration. By contrast, ECAR values 
usually start around low levels and rapidly increase over the following two 
measurements. The metabolic switch appears to occur during the early stages of the 
stress test assay but before the introduction of any modulators. 
Criterion 1 is the dominant form of abnormality, occurring most frequently (8/12 
experiments, 55/240 wells). In plates where criterion 1 is dominant, the affected wells 
appear grouped to a particular side of the well plate instead of being randomly 
distributed throughout, despite cells being seeded in a random sequence or by row using 
a multipipette.  This abnormality occurs irrespective of the variable being optimised as it 
is evident in each of the three types of optimisation experiment being performed (as 
















wells 1 2 3 4
A A01 4-Jun Platelet seeding 1 20 0.75 0.6 10 varied 6 7 3 3 1
B A06 17-Jun Platelet seeding 2 20 0.75 0.6 10 varied 6 2 1 1
C A07 23-Jun Platelet seeding 3 20 0.75 0.6 10 varied 4 9 7 1 1
D A01 24-Apr FCCP Variation 1 20 0.75 varied 10 70m 4 5 2 2 1
E A04 24-Jun FCCP Variation 2 20 0.75 varied 10 40m 4 8 6 2
F A08 30-Jun FCCP Variation 3 20 0.75 varied 10 40m 4 9 9
G A09 3-Jul FCCP Variation 4 20 0.75 varied 10 40m 4 10 10
H A02 10-Jun Glutamine Variation 1 20 0.75 0.6 10 40m varied 13 13
I A05 12-Jun Glutamine Variation 2 20 0.75 0.6 10 40m varied 5 3 1 1
J A03 16-Jun Glutamine Variation 3 20 0.75 0.6 10 40m varied 3 2 1
K A10 3-Aug Glutamine Variation 4 20 0.75 0.6 10 40m varied 3 3




Figure 3.10  OCR and ECAR bioenergetic traces (plate G). Figures show two groups of 
either normal or abnormal wells (n=10 for each group). (a) Mitochondrial stress test profile 
representing bioenergetics components of OXPHOS. (b) ECAR which represents GL. 
 
Inspection of the wells at the conclusion of the experiment revealed platelets from 
criterion 1 were aggregating to varying degrees, as illustrated in Figure 3.11. This 
aggregation occurs during the course of the experiment, as the cells begin the procedure 
in a confluent monolayer but finish in varying clustered formations. 
 
Figure 3.11  Representative microscope photos at the conclusion of the 
mitochondrial stress test assay. Images show varying degrees of platelet aggregation 
















































To ascertain whether the pH of the extracellular media might be causing a metabolic 
switch, the background wells of two glutamine (GLN) optimization experiments were 
examined (Figure 3.12). Unbuffered XF-DMEM media used in these experiments was 
initially set to a pH of 7.35 at a temperature of 37 °C. Both experiments shown are exact 
replicates which differ only by blood donor. The top charts display pH and OCR values 
from the four background wells during the course of the experiment. Figure 3.12 
highlights the similarities in both pH and OCR of the background wells. Background pH 
for each experiment starts at around 6.9 and increases during subsequent measurements 
to level out at a range of 7.0 to 7.1. OCR traces show a similar increase over the time points 
of these experiments. While both experiments have similar background pH and OCR they 
have drastically different result outcomes, as shown in the schematic of the well plate 
below each graph. Plate H has 13 abnormal wells categorised as criterion 1, while plate J 
has just 3 abnormal wells. The contrasting outcomes of these experiments appears 
independent of glutamine supplementation and pH conditions of the media used. 
Figure 3.12 Comparison of background wells from two glutamine optimization 
experiments (H and J). Top graphs show pH and OCR measurements of the background 
wells from each experiment. The bottom schematic illustrates abnormal wells from the 
corresponding experiments above. 
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3.1.3  Optimisation Results 
 
Despite the high occurrence of abnormal wells, it was possible to use the data obtained 
from the normal profiles. The loss of data that resulted from having to exclude abnormal 
or ‘outlier’ wells made comparison of valuations difficult. Figure 3.13 illustrates this 
difficulty. Four experiments from four different blood donors are compared in this bar 
graph. The number of replicate wells used in calculating the mean values is listed at the 
base of each column. Each group in all experiments had 5 wells allocated to each variable, 
but due to the exclusion of abnormal wells the replicates vary from 1 to 5 wells. 
 
  
Figure 3.13 Glutamine optimisation experiments – basal respiration. Platelets 
from four donors were assayed under varying concentrations of glutamine-supplemented 
media. Technical replicates are numbered at the base of each column. 40 x 106 platelets per 
well, FCCP = 0.6µM. Data represent mean absolute values ± standard deviation. 
 
The same data set is represented in Figure 3.14. Here each measurement is given as a 
percentage of the data set labelled GLN 0, which had no additional glutamine added to 
the XF media (XF assay media already contains 2 mM glutamine). Plate H appears most 
responsive to glutamine supplementation, but the low number of replicates used in these 
averages is unsatisfactory. Plate K had the lowest number of wells omitted and appears 






















Media Supplementation (mM of GLN)
Plate H Plate I Plate J plate K
43 
 
comparatively unresponsive to increasing concentration of glutamine. Plates I and J show 
a positive response to increasing glutamine supplementation. 
 
Figure 3.14 Glutamine optimisation experiments - % change basal. Platelets 
from four donors were assayed under varying concentrations of glutamine-supplemented 
media. Measurements given as percentage change from a baseline point designated as GLN 
0. Data represent mean values ± standard deviation. 
 
The impact of glutamine supplementation on platelet reserve capacity is also shown in 
Figure 3.15. In this graph, spare respiratory capacity is given as a percentage of basal 
respiration. Plate H again is most responsive to increased glutamine concentrations with 
supplementation of 2 mM (4 mM total) achieving the maximal effect. All further platelet 
experiments were carried out with 2 mM glutamine supplementation to bring the 
glutamine concentration to 4 mM and in-line with current literature. 
 
 
Figure 3.15 Glutamine 
optimisation experiments – 
spare capacity %. Measurements 
given as percentage change of 
basal respiration. Data represent 
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Platelet seeding density assays were also conducted to optimise the number of platelets 
seeded into each well of the XF24 cell microplates (Figure 3.16). The seeding density of 
40 million platelets per well was chosen for three reasons: 1 - cells visually appear 
confluent under microscope; 2 – OCR values lie on the linear response region in each of 
the three optimisation experiments; 3 - OCR values of at least 200 pmol/min are optimal 
for the instrument’s sensitivity. At higher densities (80 x 106 per well) a drop in OCR 
values was seen in plates A and C.  
As shown in Table 3.1, no consistent adverse effects were seen as a result of over-
confluent platelet seeding. Two of the three platelet seeding experiments produced 
results with no abnormal wells from criterion 1. In one experiment (plate C), 7 wells 
displayed a metabolic switch to glycolysis, but there was no discernible pattern in 
relation to seeding density, as wells from all densities were affected.  
 
 
Figure 3.16 Platelet seeding density experiments. Platelets from three donors were 
assayed under varying platelet densities of 10-80 x 106 cells per well.  Technical replicates 
are numbered at the base of each column. Data represent mean values ± standard deviation. 
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Other biometric parameters were examined to see if they were affected by seeding 
density. Similar declines in line with basal respiration were seen at higher seeding 
densities. The density of 40 x 106 platelets per well appears to show a positive OCR 
response in each of the parameters; however, the same problem with irregular technical 




Figure 3.17 Platelet biometric parameters from seeding density experiments. 
Platelets from three donors were assayed under varying platelet densities. Technical 
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FCCP experiments were also conducted to optimise the use of this cytotoxic ionophore. 
By shuttling protons across the inner mitochondrial membrane, this proton carrier 
collapses the proton gradient and prevents the usual PMF. This allows the ETC complexes 
to operate at their maximal rate and allows measurement of both maximal and spare 
reserve capacity. Titrating this drug is essential to both achieving the maximal spare 
reserve capacity and minimising the cytotoxic effects on the other cellular components 
for the remaining duration of the XF assay. Four FCCP optimisation experiments were 
carried out to determine the lowest FCCP concentration able to achieve the maximal 
uncoupling effect as represented by spare reserve capacity. Only one of these 
experiments produced interpretable data (Figure 3.18). The data set of 0.5 µM had three 
wells omitted as abnormalities, leaving only two remaining wells to record a mean value. 
The other three experiments had too many wells omitted due to abnormalities. Such 
inconsistencies within experiments hindered useful interpretation or comparison. It was 
not possible to reproduce results consistently due to the loss of data from abnormal wells, 
and so the use of 0.6 µM of FCCP was continued for all experiments, following the protocol 
of previous research (53). 
 
Figure 3.18 Platelet FCCP optimisation experiment - Spare Respiratory Capacity 
(%) Platelets (plate D) were assayed under varying FCCP concentrations (mM). Technical 
replicates are numbered at the base of each column. Oli = 0.75 µM, Ama = 10 µM. Data 
represent mean values ± standard deviation. 
 
  

























3.1.4  Preliminary Results 
 
Table 3.2 gives BHI calculations from the 7 experiments where this calculation could be 
made. Age, date and donor have also been included. Two of these values (D and F) have 
used a FCCP concentration that differs from the remainder. This data set is given to 
illustrate the concept of calculating BHI for donors of different ages; however, the 
experimental conditions are too irregular to enable comparison. This irregularity is due 
to the combination of having variations in experimental parameters and the resulting 
data loss from excluded wells. As detailed earlier, optimisation experiments required 
dividing the 20 available wells into groups of 5 replicates. For some experiments this 
resulted in very few normal replicates from which to make the necessary calculations. 
This is a problem that should easily be solved once optimisation experiments give way to 
normal data collection and 10 wells per donor can be used (n=10).  
To calculate BHI a normal trace is required where all biometric parameters are 
successfully measured. A negative value for any of the parameters that constitute the BHI 
results in that well being excluded from BHI calculations. Hence further data loss was 
experienced when proton leak or non-mitochondrial respiration occasionally measured 
as a negative OCR value  
 









Plate Donor Date Age 
FCCP 
 (µM) BHI 
A A01 4-Jun 21 0.6 1.56 
C A07 23-Jun  43 0.6 1.14 
D A01 24-Apr 21 1 1.4 
F A08 30-Jun 45  1.5 0.98 
H A02 10-Jun 33 0.6 1.91 
I A05 12-Jun 56 0.6 1.89 
K A10 3-Aug 31 0.6 1.4 
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3.2 Peripheral Blood Mononuclear Cells (PBMCs) 
 
3.2.1  Monocytes and Lymphocytes 
 
The protocol initially followed was designed to isolate and purify each of the three 
desired cell types (platelets, monocytes and lymphocytes) from the same blood sample 
(53). Whole blood was centrifuged and the platelet rich plasma was removed as per the 
platelet preparation protocol (chapter 2.2.1). The residual blood was then processed 
according to the monocyte and lymphocyte protocol using MACS separation. The 
resulting monocyte and lymphocyte preparations contained a high level of neutrophil 
contamination. Furthermore, the monocyte isolations also contained lymphocyte 
contamination as confirmed by flow cytometry (Figure 3.19). Further rounds of MACS 
separation purified the target cell but resulted in a yield too low for XF analysis. After 
using flow cytometry to test the Ficoll layers it was discovered that neutrophils were 
present at all density layers. This phenomenon was observed only when the whole blood 
had undergone the initial centrifugation for platelet isolation from PRP. It was decided 
from this point that the platelet centrifugation step was causing neutrophil 
contamination and should be discontinued. From this point dilute whole blood was 






Figure 3.19 Representative flow cytometry 
result from a monocyte preparation using 
MACS separation. Lymphocytes 7%, Monocytes 






3.2.1  T Lymphocytes (T-cells) 
 
Lymphocytes can be divided into three cell types: T cells, B cells and natural killer (NK) 
cells. T cells were isolated using negative selection to remove target cells (monocytes, B 
cells, NK cells) from a PMBC density isolation. On average, 20-35 x 106 T cells were 





The mitochondrial stress test analysis was conducted on varying T cell concentrations to 
determine the optimal seeding density (Figure 3.20).  
 
 
Figure 3.20 T cell mitochondrial stress test optimisation assay.  (a) basal and (b) 
maximal respiration for T cells from two donors. Oli = 0.60 µM, FCCP = 0.6µM, Ama = 10 µM. 
Data represent mean values from 4-5 wells ± standard deviation. 
 
Basal respiration displayed a linear response to increasing cell densities between 2 x 105 
and 8 x 105 cells per well. The OCR values over this range are marginally low for the 



















































instrument’s sensitivity. Maximal respiration appears to increase in a linear fashion in 
the range of 2 x 105 and 6 x 105 cells per well. This relative increase appears to cease at 
higher densities of 8 x 105 cells per well. Visually, T cells appear confluent at a density of 
6 x 105 cells per well (Figure 3.21). Based on these findings the density of 6 x 105 T cells 




Figure 3.21 Microscopic images of varying T cells densities. Cells plated in a XF24 cell 





Results from two FCCP optimisation assays (Figure 3.22) show a non-linear 
concentration response in OCR with a slope of the line decreasing at higher dose 
concentrations. A concentration of 1 mM was chosen as the optimal dose to achieve 
maximal OCR and to lessen the impact on OCR of small variations in drug concentrations 
that may persist between experiments.  
 
Figure 3.22  T cell FCCP Response - Reserve Capacity. Reserve capacity is shown for T 
cells from two donors (A02, A03). Oli = 0.60 µM, FCCP = varied, Ama = 10 µM. Data represent 
mean values from 3-5 wells ± standard deviation. 
 
The purity of T cell preparations was tested using CD3-PE monoclonal antibody 
incubation and flow cytometric detection (Figure 3.23). The average cell preparation 





Figure 3.23  Flow cytometry 
analysis of purified T cells using 






















Representative results from a T cell optimisation experiment are shown in Figure 3.24. 
Here the bioenergetics trace is given for a cell seeding density experiment. The OCR 
values are normalised to cell number (105 cells per well) and the various densities are 
grouped into a single data set. Of the 20 wells assayed, 9 were ultimately excluded as 
abnormal wells or outliers. The reserve capacity of T cells is very evident in the raw trace 
and is quantified in Figure 3.25, which shows each bioenergetics parameter as a 











Figure 3.24  Representative bioenergetics trace of a T cell mitochondrial stress test. 
Donor A01. Normalised to 105 cells per well. Oli = 0.6 µM, FCCP = 0.6µM, Ama = 10 µM. Data 




































Figure 3.25 T cell bioenergetic parameters - % of basal. Donor A01. Normalised to 105 
cells per well. Oli = 0.6 µM, FCCP = 0.6µM, Ama = 10 µM. Data represent mean values from 
11 wells ± standard deviation. 
 
A demonstration of a T cell BHI valuation is given in Figure 3.26, which shows the BHI for 
the same experiment shown in Figures 3.21 and 3.22. Again, the exponents for each 







Figure 3.26 Representative T cell BHI.  A single 
metric encompassing four T cell bioenergetic parameters 
measured by the mitochondrial stress test. Donor A01, n 









































































Chapter Four: Discussion 
 
In an effort to measure mitochondrial function in circulating blood cells I trialled three 
isolation and purification techniques to prepare cell solutions for XF analysis. Following 
successful isolation, platelets and T cells were assayed by the mitochondrial stress test to 
reveal their characteristic bioenergetic parameters as determined indirectly by the 
dynamic measurement of oxygen consumption rates under experimentally controlled 
conditions. 
 
4.1 Summary of results 
 
4.1.1 Cell Isolations 
 
Both platelets and T cells were successfully isolated and purified from freshly drawn 
blood within 3-4 hours of collection. PGI2, through its inhibition of platelet activation 
allowed repeated rounds of centrifugation and re-suspension without aggregation 
occurring, and sufficient platelets were purified from 9 ml of blood to seed 5-6 wells at 
40 x 106 platelets per well.  T cells were purified through negative selection to yield a 
~90% pure cell isolate. This is in line with purity results reported in similar protocols 
(51). EDTA vacuum tubes showed no observed effect on cells bioenergetics consistent 
with prior reports (56). Nine ml of whole blood produced enough T cells to seed 6-7 wells. 
Both platelets and T-cells displayed a homogenous monolayer when plated onto XF cell 
plates before commencement of the mitochondrial stress test.  
 
Attempts to follow a recently published protocol for the isolation of platelets, monocytes 
and lymphocytes from the same blood collection was unsuccessful due to the failure to 
produce suitably pure isolations (56). It was found that the PRP centrifugation step had 
an undesirable effect on Ficoll density separation and resulted in neutrophil 
contamination through all layers of the Ficoll separation. The positive selection for 
monocytes using magnetic bead labelled antiCD14 antibodies and MACS separation failed 
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to adequately elute away lymphocytes.  The presence of lymphocytes in the CD14 positive 
flow-through collection may be due to activation of lymphocytes in the presence of 
monocytes. Activation can cause CD14 antigenicity in the lymphocytes (57) and if this 
change occurs it becomes redundant to positively select monocytes by using CD14 
positive selection from a PBMC mixture. This result brought into question the merit of 
using CD14 positive selection to achieve pure isolations of monocytes. It has been 
previously reported that the CD14 antigen is not solely unique to this cell type (58). It 
was decided that rather than isolating all three cell types by one continuous preparation 
as the protocol set forth, it was more advantageous to conduct individual cell 
preparations. 
 
4.1.2  Unexpected Results 
 
Both platelet and T cell XF assays experienced loss of data due to the exclusion of wells 
that displayed uncharacteristic bioenergetics OCR or ECAR traces. Throughout the 12 
platelet experiments it became evident that these unexpected results could be 
categorised by four patterns and that criterion 1 was the most frequently occurring. 
While the other three classifications could be accepted as outliers due to random and 
infrequent occurrence, that was not the case for criterion 1. In these wells it appeared 
that the cell population switched energy metabolism to make a much greater use of 
glycolysis. The metabolic switching was seen to occur independent of cell density, 
glutamine, extracellular media concentration or pH. It was also seen to occur in a non-
random fashion, typically occurring in groups in one area of the cell plates despite the 
plating being carried out in with a multipipette. All wells began with homogenous and 
confluent cell monolayers but many displayed varying degrees of clumping by the end of 
the assay. Some evidence of platelet aggregation was seen at the conclusion of the 
experiment however normal wells also exhibited aggregation on many occasions so this 
was not a phenomenon only seen in criterion 1 wells. By the conclusion of the assay all 
modulating drugs had been injected into the XF media and these may be influencing the 
appearance of cells when examined under microscope.  
There is a possibility that the experimental conditions may have caused activation of 
platelets in abnormal wells classified as criterion 1. This is a surprising outcome that is 
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contrary to some reports. Most notably, Cardenes et al. showed that the percentage of 
activated platelets did not change from before to after the XF assay and they concluded 
that XF measurement did not stimulate platelet activation (44). It is worth noting that 
this group uniquely uses an erythrocyte lysis buffer during their cell isolation. Red blood 
cells (RBCs) are known to enhance platelet reactivity (59) and so this additional 
precautionary step may be prudent in case of RBC contamination. Similarly, Chacko et al. 
used an activated control group to test for platelet activation during the preparation stage 
and  found that platelets and PBMCs showed no evidence of activation (51). In this same 
paper the number of replicates varied from 3-5 per group and leads one to suspect some 
wells may also have required exclusion. This same paper also mentions that artificial 
activation can result in clumping of cells but gives no record of this occurrence. The risk 
of platelet activation is also mentioned by Kramer et al. who suggest platelets be allowed 
to sit longer between the PRP isolation and the rest of the purification stages (51). Despite 
the occasional mention of the risks of platelet activation none of these papers detail any 
occurrence of outlier wells or mention the exclusion of abnormal wells of any form. 
The bioenergetics traces for criterion 1 show an early and definite switch to glycolysis as 
seen by a rapid increase in ECAR coupled with a sudden decline in OCR. A paper released 
this year looking at the metabolic plasticity of platelets provide insight into what may be 
occurring (49). Here the author shows that thrombin induced activation of platelets 
stimulates both OXPHOS (25%) and GL (300%). This documented increase in OXPHOS 
during platelet activation strongly contradicts what was observed to occur in criterion 1 
wells. This paper explains how platelets are able to make a compensatory switch between 
metabolic systems and that platelets displaying metabolic plasticity during resting state 
and thrombin induced activation. As well as D-glucose and pyruvate, platelets have the 
ability to use both fatty acids (60) and L-glutamine (61) as fuel to provide substrates for 
the TCA cycle via beta-oxidation and glutaminolysis respectively. Ravi et al. also showed 
that when these two metabolic systems are excluded, whether it be by inhibition or 
substrate depletion, platelets are able to compensate by generating ATP entirely through 
glycolysis (49). I believe this may be occurring in the case of criterion 1 wells. Platelet 
activation may not necessarily be occurring but the platelets metabolic elasticity is 
allowing a metabolic switch from OXPHOS to glycolysis. This switch seems to be induced 
by the early measurement cycle and leads me to speculate that the formation of the 7 µl 
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microchamber may be limiting substrate availability over the four minute measurement 
period and may be triggering the metabolic switch to glycolysis. This may be overcome 
by experimentally titrating substrate concentrations to find the level required to ensure 
they each remain in excess during the formation of the transient microchamber. Failing 
this, another option would be to trial shorter time periods of measurement, however this 
goes against manufacturer’s recommendations. 
 
4.1.3 Optimisation of Experimental Conditions 
 
Following successful cell isolations, optimisation XF assays were conducted on platelets 
and T cells to determine the optimal values of important experimental condition such as 
seeding density, FCCP concentration and glutamine supplementation. 
 
The importance of optimising glutamine (GLN) within the extracellular media was only 
realised after the release in April of a recent study by Ravi et al. (49). Here it is shown that 
GLN depletion from media resulted in significant effect on platelet bioenergetics. Before 
this paper no additional GLN was added when making up the XF-DMEM media, other than 
the 2 mM GLN present in XF assay medium. By late in the year we had XF base medium 
available (which does not contain any GLN) however all GLN assays were carried out 
prior to this with medium already containing 2 mM GLN. The research by Ravi et al. 
showed that bioenergetics parameters (basal, ATP linked, proton leak, maximal and 
reserve capacity) all have lower measured OCRs when the assay medium is depleted of 
GLN, and that all bioenergetics parameters achieve maximal OCR measures with 4 mM of 
GLN supplementation. Plasma contains between 500-750 µM of GLN (62) meaning 
optimal concentrations of GLN for XF analysis is ~8 fold higher. The platelet optimisation 
results (Section 3.1.3) show maximal OCR values for basal respiration after 4 mM of 
additional GLN has been added, making the total GLN supplementation 6 mM. This 2 mM 
excess suggests the quality or availability of the 2 mM GLN inherent in the purchased 
medium may be questionable. The reserve capacity results showed a GLN concentration 
response in one of three experiments and in one experiment the maximal response was 
achieved when a total of 4 mM GLN was present in agreeance with the findings of Ravi et 
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al. As with all optimisation results the inconsistent number of replicates available is a 
major hindrance to meaningful interpretation and further assays are needed to 
conclusively test both the quality of GLN used and the concentration response. Until this 
time 4 mM GLN total supplementation will continue to be followed. 
 
The need to optimise conditions in order to both maximise measured bioenergetics 
parameters and to minimise system variation in measurement is of great importance 
when comparing results from separate research groups. A summary of the critical 
experimental conditions of the leading researchers in this field is provided in Table 4.1. 
GLN supplementation is only performed by Chacko and Ravi, with all other groups not 
including GLN in the XF medium or optimising its concentration. Similar inconsistencies 
are seen in glucose (GLU) supplementation, equilibration time, FCCP concentration and 
cell density. 
 
Cell density optimisation experiments led to the conclusion that 40 x 106 platelets and 60 
x 104 T cells should be seeded into each well. These values are higher than the average 
with Cardenes et al. being the only other group to use more than 25 x 106 platelets per 
well. They showed that basal and maximal respiratory rates were dependant on seeding 
density and OCR showed a linear response between 5-100 x 106 platelets per well and 
consequently chose 50 x 106 as their seeding density. We observed a similar linear 
response (Figure 3.16) however in two of three assays this linearity only held at lower 
seeding densities. Lower OCR was recorded at higher densities of 80 x 106 platelets per 
well. A similar effect was observed in T cell experiments (Figure 3.20). This reduction in 
OCR is possibly due to the loss of cells to the extracellular media during repeated rounds 
of measurement, or a reduction of OXPHOS caused by proximity of platelets to one 
another in the over-confluent wells.  
 
Optimisation experiments showed that abnormal results were occurring independently 
of these optimisation parameters. It is understandable that each research facility will 
display variation in optimal parameters and our particular values chosen, while different, 
are still similar to those used in other research groups. 
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Table 4.1 Summary of experimental conditions for XF assays using blood cells. 










Platelets Cell  
number 


















Cell number 5  - 50 x 106 0.7 
Kramer, 
2014 
Leukocyte Protein - - 25 x 104 0.6 
Kramer, 
2014 





Protein 5.5 4 10 x 106 0.6 
Xu, 
2015 






4.1.4 Preliminary Results 
 
Results from similar experiments are limited to a few studies and variations in 
experimental conditions and protocols used make comparison between studies difficult. 
In other studies normalisation of experimental results has been made by representing 
OCR values either per µg of protein or per cell number (Table 4.1). My attempts to 
optimise platelet experiments by protein assay (Methods 2.2.4) failed to suitably reduce 
well-to-well variation or to accurately determine the protein content of every well. The 
protein assay resulted in increased data variation and further exclusions due to abnormal 
results meant that normalising each well to protein content was inexpedient. As such, I 
chose to normalise data to cell number and to represent bioenergetic parameters as a 
percentage of basal respiration to counteract any variation in cell seeding number that 
may occur between experiments. More direct comparisons can be drawn with those that 
also used cell number to normalise results. Cardenes et al. showed that platelets seeded 
at 50 x 106 cells per well had absolute basal OCR values ~92 pmol O2/min. This is much 
lower than measurements recorded in platelet optimisation experiments (Section 3.1.3) 
which typically measured around 200-300 pmol O2/min. Fink et al. using 20 x 106 
platelets per well measured basal OCR around 120  pmol O2/min which if adjusted to cells 
number would be in agreeance with my measurements. Kramer et al. using densities of 
25 x 106 platelets, also gives average basal values of 200 ± 20 pmol O2/min. Their results 
are also normalised to cell number but has no added glutamine to the assay medium.  
 
Platelet reserve capacity is known to be characteristically low when compared to other 
cell types (51). Successful optimisation of both FCCP and GLN was needed to consistently 
produce positive values of reserve capacity. Figure 3.6 shows a representative 
experiment where reserve capacity was measured as 26% of basal respiration. This is in 
agreeance with Fink et al. who also show reserve capacity of 25% and is similar to the 
18% presented by Chacko et al. Other studies, such as Xu et al. (48) failed measure any 
reserve capacity in platelets which maybe reflective of the insufficient optimisation 




Overall these results agree in part with published studies. The desired bioenergetics 
parameters were successfully measured and in some instances a BHI was calculated. The 
BHI was conceived by Chacko et al. with the rationale that measured biometric 
parameters can be grouped to represent positive and negative aspects of bioenergetics 
function, and then fitted into an index equation accordingly (28). The index was then 
tested under the influence of a strong oxidative stressor to ensure the metric displays the 
correct responsiveness to detrimental condition. Each parameter is given an exponent 
which in the default form is set to 1. The authors suggest that weightings could be applied 
to each exponent based on biological significance or pathological relevance of the 
underlying condition being measured. While BHI data is beginning to be published (47, 
63) until uniformity in calculation and protocol design is adopted, direct comparisons 
cannot be drawn between studies. The variability in results that I observed in this study 
also suggests that there may be a significant problem in standardizing BHI obtained 
between labs. This reiterates the need to carefully optimise experimental conditions and 
to maintain consistency and uniformity in protocol to allow making comparisons 
possible. Once this consistency is achieved, metrics like the BHI may be used to make fast 
and non-ambiguous comparisons between individuals and between separate studies.  
 
 
4.2 Strengths and limitations 
 
The greatest limitation in this study was the limited number of wells in which to perform 
the XF assay. The Seahorse instrument available uses 24-well cell-plates and 4 of which 
are needed to assess background conditions of the experiment. Optimisation experiments 
ideally required groups of 5 wells for each variable, such as FCCP concentration, limiting 
the assay to only 4 groups per experiment. On too many occasions a group which 
contained 5 replicates was reduced to less than 3 due to the problems experienced with 
exclusion of abnormal results. This was the main hindrance in being able to successfully 
replicate results in order to be confident the result was optimal. Ravi et al. recently used 
a Seahorse XF96 instrument which uses a 96 well plate which provides much greater 
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scope to deal with omission of abnormal results and allows for more variables to be 
compared within a one experiment. 
 
4.3 Future Directions 
 
Until the abnormal results problem is addressed it is not possible to generate high quality 
reproducible results. If metabolic switching is being triggered by substrate limitations 
during the formation of the microchamber then one possibility would be to lessen the 
current measurement time. The measurement period of four minutes is recommended 
by the instruments instruction manual based on the sensitivity of the fluorometric probes 
and the absolute OCR values that are typically being produced by platelets and PBMCs.  
Using an erythrocyte lysis buffer during the platelet preparation may also be advised to 
try prevent the occurrence of criterion 1 s well as using XF base medium. Testing of the 
supplements such as GLN and GLU may be necessary to ensure quality and consistency 
of conditions. 
Once the protocol has been successfully developed then it should be tested on a positive 





Platelets and T cells continue to demonstrate potential as quick and easily accessed cells 
from which to measure human mitochondrial function in intact human cells. My research 
supports others findings that blood cells such as platelets and lymphocytes each have a 
distinct and measurable set of biometric parameters. Given optimal, uniform and 
consistent experimental parameters this methodology should be able to quickly assay a 
large cohort of people. It is not yet clear whether measuring multiple bioenergetics 
parameters and representing these as a single metric may allow for detection of 
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